Loading...
•
Dec 31, 2025
Tyra Biosciences Q4 2025 Earnings Report
Tyra Biosciences reported increased operating expenses and a wider net loss in Q4 2025 as it advanced its Phase 2 clinical programs under the dabogratinib 3x3 strategy.
Key Takeaways
Tyra reported a Q4 2025 net loss of 33834000 driven by 36516000 in total operating expenses, reflecting continued investment in dabogratinib clinical development. Cash, cash equivalents and marketable securities totaled 256003000 at quarter end, providing runway through at least 2027.
Total operating expenses were 36516000 in Q4 2025.
Net loss was 33834000, or 0.57 per share.
R&D expenses increased year-over-year to 28186000.
Cash, cash equivalents and marketable securities totaled 256003000 at quarter end.
Forward Guidance
Tyra expects to advance three Phase 2 studies under its dabogratinib 3x3 strategy, with interim data readouts expected in 2026 and cash runway projected through at least 2027.
Positive Outlook
- Executing dabogratinib 3x3 strategy across three potential blockbuster indications.
- Phase 2 SURF302 initial data expected by end of 1H 2026.
- Phase 2 BEACH301 interim results expected in 2H 2026.
- Strong cash position supporting operations through at least 2027.
- Expanded clinical site footprint in Q4 2025.
Challenges Ahead
- Net loss widened year-over-year.
- Operating expenses increased due to clinical program expansion.
- No product revenue generated.
- Continued dependence on capital markets.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...